atrial fibrillation

81 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

A prespecified analysis of the AZALEA-TIMI 71 trial demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older patients with atrial fibrillation, potentially offering a safer al

Section: CardiologyFeb 5, 2026

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

This large-scale real-world analysis reveals that GLP-1 receptor agonist therapy reduces atrial fibrillation recurrence by 18% and lowers all-cause mortality in obese patients following catheter ablation, highlighting a potent upstream stra

atrial fibrillation

Latest news

Redefining Anticoagulation Safety in the Elderly: Abelacimab Drastically Reduces Bleeding Risk in Phase 2b AZALEA-TIMI 71 Analysis

GLP-1 Receptor Agonists Significantly Reduce Atrial Fibrillation Recurrence and Mortality Following Catheter Ablation in Obese Patients

GLP-1 Receptor Agonists Associated with Lower Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients

Ultra-Early ILR Implantation Post-Cryptogenic Stroke Dramatically Improves Silent AF Detection: Insights from the CRIPTOFAST Trial

Low-Dose Rivaroxaban Fails to Halt Cognitive Decline in Low-Risk Atrial Fibrillation: Results from the BRAIN-AF Trial

Genetic Risk Profile Predicts Stroke Prevention Benefit From Continuous Atrial Fibrillation Screening: A Secondary Analysis of the LOOP Study

Proteomic Signatures in Atrial Fibrillation: Deciphering the Risk of Heart Failure Hospitalization and Ejection Fraction Phenotypes

Rethinking Rhythm Management: Catheter Ablation Outperforms Medical Therapy in Atrial Fibrillation Patients with High Comorbidity Burden

Predicting Stroke Recurrence: MRI Markers Outperform Location in Risk-Stratifying Patients with ICH and Atrial Fibrillation

Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care

Is Indefinite Heart Failure Therapy Necessary After AF Rhythm Control? Insights from the WITHDRAW-AF Trial

Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF

Rethinking First-Line Anticoagulation in Older Adults: Real-World Evidence Challenges Conventional AFib Management

Albiglutide Reduces Cardiovascular Risks in Patients With Type 2 Diabetes Regardless of Atrial Fibrillation Status: Insights From Harmony Outcomes

Significant 1-Year Risk of Cardiovascular Events in Cognitive Impairment Highlights Safety Concerns for Anti-Amyloid Therapy

Genetic Susceptibility and Elite Rowing: The Dual Drivers of Atrial Fibrillation Risk in Former Athletes

Distinct Neuroimaging Signatures: Atrial Fibrillation and Atherosclerosis Drive Divergent Vascular Brain Lesion Patterns

Low Potassium Levels Linked to Five-Fold Increase in Daily Atrial Fibrillation Risk: Insights from Continuous Monitoring

Safety Profile Favors Apixaban Over Rivaroxaban in High-Risk Patients with Atrial Fibrillation and Peripheral Artery Disease

Is Female Sex a Truly Independent Risk Factor for Stroke in Atrial Fibrillation? Insights from a Large European Cohort